Given the recent approval of a number of bispecific antibodies and several ongoing R&D efforts focused on evaluating the potential of such candidates against various disease indications, this sector of the pharmaceutic industry has garnered significant interest of stakeholder
The USD 16.8 billion (by 2035) financial opportunity within bispecific antibodies market has been analyzed across the following segments:
§ Therapeutic Area
§ Autoimmune Disorders
§ Genetic Disorders
§ Hematological Malignancies
§ Ophthalmic Disorders
§ Skin Cancers
§ Solid Tumors
§ Mechanism of Action
§ Cytokines Retargeting / Neutralization
§ Dual Ligands Blocking
§ Resistance Factors Co-targeting
§ Targeting Tumor Angiogenesis
§ T-Cell Retargeting / Activation
§ Others
§ Target Antigen
§ C5-Albumin
§ CD20 x CD3
§ CD3 x BCMA
§ CD3 x CD19
§ EGFR x cMET
§ EpCAM x CD3
§ Factor IXa x Factor X
§ gp100 x CD3
§ HER2 x HER2
§ PD-1 x CTLA-4
§ PD-L1 x TGFβ
§ TNF-α x HSA
§ VEGF x DLL4
§ VEGF-A x ANG2
§ Antibody Format
§ Asymmetric
§ Fragments
§ Key Players
§ Akeso Biopharma
§ Alexion
§ Amgen
§ Genmab
§ Immunocore
§ Janssen Research & Development
§ Linton Pharm
§ Merck
§ OncXerna Therapeutics
§ Pfizer
§ Roche
§ Taisho Pharmaceutical
§ Zymeworks
§ Key Geographical Regions
§ Asia
§ Europe
§ North America
§ Rest of the World
The Bispecific Antibodies Market, 2023-2035, report features the following companies, which we identified to be key players in this domain:
§ Akeso Biopharma
§ Alphamab Oncology
§ Amgen
§ Merck
§ Regeneron
§ Roche
§ Xencor
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape of Approved and Clinical Therapies
5. Market Landscape of Preclinical Therapies
6. Key Insights
7. Technology Assessment Framework
8. Big Pharma Players: Benchmarking Analysis
9. Company Profiles
10. Partnerships and Collaborations
11. Contract Services for Bispecific Antibody Therapeutics
12. Clinical Trial Analysis
13. Case Study: Regulatory Guidelines for Bispecific Antibodies
14. Case Study: Promotional / Marketing Strategies
15. Market Forecast and Opportunity Analysis
16. SWOT Analysis
17. Concluding Remarks
18. Executive insights
19. Appendix 1: Tabulated data
20. Appendix 2: List of Companies and Organizations
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
You may also be interested in the following titles:
| Decentralized Clinical Trials / Virtual Clinical Trials Market |
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Русский